



Entrepreneurial &
Skilled Education
for the Future



Volume 5, Issue 2 - MAY 2026

IQ RESEARCH

A Quaterly Journal

ISSN: 2790-4296 (Online)

ISBN: 978-9956-504-74-9 (Print)

Published by IQRJ publications
www.iqresearchjournal.com



EDITORIAL BOARD

Editor-in-Chief

- ◆ Atanga D. Funwie (Professor) — Kesmonds International University / Nile University of Science & Technology / Green Hope University Somalia

Deputy Editor-in-Chief

- ◆ Dr. Mvogo Eloundou Guy Dieudonné, PhD, Public Health, Tropical Medicine and Infectious Diseases / Kesmonds International University

Associate Editor-in-Chief

- ◆ Tchouaffe Tchiadje Norbert (Professor) — Kesmonds International University / Massachusetts Institute of Technology USA / Pan African University

Editorial Assistants

- ◆ Professor Tchakounte Franklin — Kesmonds International University / University of Ngaoundere
- ◆ Professor Akah Roland Tiagha — Kesmonds International University / Walter Sisulu University South Africa
- ◆ Professor Guiherme Schneider — Mexico
- ◆ Professor Charles Fokunang — Cameroon Ethics Society / University of Yaounde 1
- ◆ Professor Tassang Ndah Andrew — Kesmonds International University / University of Buea
- ◆ Professor Daniel Tata — Switzerland
- ◆ Professor Truly Bush — Germany
- ◆ Professor Abraham Pius — The Academy of Advance Science, United Kingdom
- ◆ Professor Celestina Neh Tassang — University of Buea
- ◆ Professor Letlole Gabriel Gonnafela — Gonnafela Institute South Africa / Kesmonds International University
- ◆ Professor Patricia Samkia Asongwe — Ministry of Higher Education Cameroon
- ◆ Professor Sama Dobit — University of Yaounde I
- ◆ Professor Tony Ogiemen — American Heritage University of Southern California, USA
- ◆ Professor Gabriel Lopes — Unilogos University, USA and Brazil
- ◆ Professor Nukenine Elias — University of Ngaoundere
- ◆ Professor Neossi Guena Mathurin — University of Ngaoundere / Ngaoundere Regional Hospital
- ◆ Professor Angwanade Wilson — University of Ngaoundere
- ◆ Professor Esther Ngah — University of Ngaoundere
- ◆ Professor Yongho Shiwoh Louis — Kesmonds International University
- ◆ Professor Asakizi Nji Augustine — Kesmonds International University
- ◆ Professor Rudolph Q. Kwanue — Rudolph Kwanue University Liberia
- ◆ Professor Mustaf Abdulle — President Green Hope University Somalia
- ◆ Professor Mathan Muse — Green Hope University Somalia / Nile University of Science & Technology
- ◆ Professor Lawrence Mwelwa — Queens College Zambia
- ◆ Professor Ibrahim Abdi — Green Hope University Somalia / Nile University of Science & Technology
- ◆ Professor Hussein Tohow — VC Green Hope University Somalia
- ◆ Professor Henry N. Fonjock ,B.A, ACC,BIS Cert,MBA,PhD— Cameroon Cooperative Credit Union
- ◆ Professor Zahir Shah — Professional Development Research Institute Pakistan
- ◆ Professor Brian Siamani — Dean Faculty of Medicine, Gideon Roberts University Zambia
- ◆ Professor Ernest Mutale — Ministry of Health Zambia
- ◆ Professor Kouam Lawrence — Kesmonds International University / University of Ngaoundere
- ◆ Professor Pascal Scheneller — Germany
- ◆ Professor Francis Pol Lim — Philippine
- ◆ Professor Mvondo M. Manuella — Kesmonds International University / University of Ngaoundere
- ◆ Professor Tamo Simo Richard — Kesmonds International University / University of Ngaoundere
- ◆ Professor Fodouop Simeon Pierre Tchegaing — Kesmonds International University / University of Ngaoundere
- ◆ Professor Elie Baudelaire — EMIE Business School Paris France
- ◆ Professor Sundjo Fabien — Kesmonds International University / University of Bamenda
- ◆ Professor Gidoen Mwanza — Gidoen Robert University Zambia

- ◆ Dr. Christina Jean Rahm — Institute of Clinical Research USA
- ◆ Dr. Oscar Monono — Ballbridge University
- ◆ Dr. Feugueng Micheal — Kesmonds International University United Kingdom
- ◆ Dr. Penya Elvis Che — Kesmonds International University / St John Paull II University Cameroon
- ◆ Dr. Shei Claude Nfor — Shalom Institute Cameroon
- ◆ Dr. Kabonbe Achile — Kesmonds International University / University of Ngaoundere
- ◆ Dr. Doudou Raisa — Ministry of Scientific Research Cameroon
- ◆ Dr. Zilefac Ebenezer Nwetlagwung — Kesmonds International University / Southeast University China

Editorial Secretaries

- ◆ Gana Christophe — Kesmonds International University
- ◆ Kalwa Yvette — Kesmonds International University
- ◆ Eng. Benson Lugalia — Kesmonds Group Limited
- ◆ Eng. Pokam Tchinda Martial — Kesmonds International University / University of Ngaoundere
- ◆ Dr. Kelly Kesten Manyi Atanga — Kesmonds International University / Jining Medical University, China
- ◆ Dr. Pauline Wanjiru Gititha — Kesmonds International University
- ◆ Dr. Eng. Anyangwe C. Anyangom — Kesmonds Group Limited, Kesmonds Institute of Technology

Editorial Board Members

- ◆ Prof. Nicolas Guanzon Ong, Ph.D. — Department of Teaching Languages, University of Science and Technology of Southern Philippines
- ◆ Prof. Ibrahim Hussein — Kesmonds Research Institute Uganda
- ◆ Prof. Zapryan Assen — Higher School of Security and Economics, Plovdiv
- ◆ Prof. Surendra Kumar Gautam — Department of Chemistry, Tri-Chandra Campus, Tribhuvan University, Kathmandu, Nepal
- ◆ Prof. SENHADJI L. — Oran University Hospital, Department of Anesthesia-Intensive Care
- ◆ Prof. Sabyasachi Pramanik — Department of Computer Science and Engineering, Haldia Institute of Technology
- ◆ Prof. Meron Mersha — Quantum Optics and Information, Arba Minch University, Ethiopia
- ◆ Prof. Dr. Zahir Shah — Kesmonds Research Institute, Pakistan
- ◆ Prof. Dr. Bond Richard — California South University (CSU), Irvine, California, USA
- ◆ Prof. Dr. Abubakar Mohammad — University of Technology, Baghdad, Iraq
- ◆ Prof. Charlanne Miller — LIGS University Hawaii, Canada
- ◆ Prof. Ali Usman — (Ethiopia)
- ◆ Prof. Ali Abdul-Hussain Ghazzay — Department of Biology, University of AL-Qadisyah, Iraq
- ◆ Prof. Nana Anabel — (Ghana)
- ◆ Dr. Leonard Ake — Maitre-Assistant du CAMES, Enseignant-chercheur, Universite Boubacar Ba de Tillaberi
- ◆ Dr. Wilson Dabuo Wiredu — MOCS, VC Academics Affairs, DMTU, Ghana
- ◆ Dr. Wansso Blakwe Ahmed
- ◆ Dr. Vijay Ramkisan Lakwal — Department of Zoology, Science and Commerce College, Jalgaon (MS), India
- ◆ Dr. Veronica Blade — (Algeria)
- ◆ Dr. Velinga Ndolok Aime Cesaire — Ph.D. in Public Health Epidemiology, UNDP Public Health Development Program
- ◆ Dr. Uthman Simeon Adebisi — Obafemi Awolowo University, Nigeria
- ◆ Dr. Tumi Humphred Simoben — Ph.D. in Public Health, Kesmonds Research Institute
- ◆ Dr. Toffic Abdel Hassan — Plant Protection Research Institute, Agricultural Research Center
- ◆ Dr. Thomas Abraham — Department of Hotel Management, Gondar, Ethiopia
- ◆ Dr. Tchifam Berthe — Ph.D. in Public Health Epidemiology, Faculty of Medicine Garoua Cameroon
- ◆ Dr. Tatoh Adeline Manjuh — Ph.D. in Healthcare Administration, Limbe Referral Hospital Cameroon
- ◆ Dr. Tateukam Alphonse — Doctor of Clinical Medicine, Kesmonds Research Institute
- ◆ Dr. T. Christina Mondimu — University of Gondar, Ethiopia
- ◆ Dr. Surachita Basu — (Bangalore, India)
- ◆ Dr. Sujita Darmo, ST., MT — Mechanical Engineering, Mataram University, Indonesia
- ◆ Dr. Shehuri Sharon — Department of Botany, Faculty of Biosciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria
- ◆ Dr. Rofrigo Jose Pablo — Universidad Empresarial De Costa Rica
- ◆ Dr. Rintu Sayak — (India)
- ◆ Dr. Resham Kumari — Professor Assistant of Agricultural Zoology, Plant Protection Department, Sohag University, Egypt
- ◆ Dr. Renato Dan A. Pablo II — CSPE, Mabalacat City College

- ◆ Dr. Ranendu Dutta Pukayastha — S.J.N.P.G College, Lucknow, India
- ◆ Dr. Rajinder Singh Sodhi — Guru Kashi University, Ilorin, Nigeria
- ◆ Dr. Rajat Mrinal Kanti, PhD, D. LITT — Physiotherapist, NIMHANS, Bangalore, India
- ◆ Dr. Rafah Almutarreb — School of Computer Science and Technology, Algoma University, Canada
- ◆ Dr. Rabindra Das Sinha — (Chennai, India)
- ◆ Dr. R. Francis Kaundra — DMI-St. Eugene University, Great North Road, Chibombo District, Lusaka, Zambia
- ◆ Dr. Priyanka Weerasekara — Faculty of Social Sciences & Languages, Sabaragamuwa University of Sri Lanka
- ◆ Dr. Pawan Thapa — Department of Geomatics Engineering, School of Engineering, Kathmandu University, Nepal
- ◆ Dr. Osman Ibrionke — Abia State University Uturu, Nigeria
- ◆ Dr. Osama Mohamed Anwar Nofal — Emeritus Professor, National Research Centre
- ◆ Dr. Onwubere Isabella — Sub-Dean, Samuel Obiajulu University, Osun State, Nigeria
- ◆ Dr. Onodugu Obinna Donatus — Department of Mathematics, Faculty of Physical Sciences, Abia State University, Nigeria
- ◆ Dr. Ola Sayed Mohamed Ali — Girls-AL-Azhar University, Cairo
- ◆ Dr. Okpala Sunday Ocheni — University of Mosul, College of Science, Biology Dept.
- ◆ Dr. Obike Godwill Ukamaka, M.Sc, Ph.D. — (Medical Microbiology), Jos, Plateau State, Nigeria
- ◆ Dr. Obafemi Emmanuel — Adekunle Ajasin University Akungba Akoko, Ondo State
- ◆ Dr. Nzuzi Rafael — Bakhita African Schools, Butembo
- ◆ Dr. Nwatu Celestine Chibuzu — Rivers State University, Nigeria
- ◆ Dr. Nouma Simon Joachim — Ph.D. in Political Economics, Consultant and Auditor Bank of Central African States
- ◆ Dr. Ngwa Mathias — Faculty of Laws and Political Sciences, University of Dschang, Cameroon
- ◆ Dr. Nazar Hassan — PMAS Arid Agriculture University, Rawalpindi
- ◆ Dr. Nadia Jamil — Department of Environmental Sciences, Hazara University, Mansehra
- ◆ Dr. Mulani Moshin Anware — Sant Ramdas Art's, Commerce and Science College, Maharashtra
- ◆ Dr. Muhammad Farooq — Assistant Professor (Economics), Okara University, Pakistan
- ◆ Dr. Mohammad Usman Awan — Centre for Biotechnology and Microbiology, University of Swat
- ◆ Dr. Mohamed Mustaf Abdulle — Green Hope University Somalia / Nile University of Science & Technology
- ◆ Dr. Mochammad Munir Rachman, M.Si. — PGRI Adi Buana University Surabaya, Indonesia
- ◆ Dr. Mahmoud Magdy Abbas — Plant Nutrition Dept., Dokki, Giza, Egypt
- ◆ Dr. Lukong Hubert Shalanyuy — Kesmonds Research Institute
- ◆ Dr. Liela Meta — Malla Reddy Institute of Technology and Science
- ◆ Dr. Kheambo Didier — Ph.D. in Healthcare Administration, Kesmonds Research Institute
- ◆ Dr. Khan Aneeka Habib — College of Business Administration, International University of Business Agriculture and Technology, Dhaka, Bangladesh
- ◆ Dr. Kabul Amid Aabbasi — University of Karachi, Pakistan
- ◆ Dr. Jesica Gate — (France)
- ◆ Dr. Javnyuy Joybert, MBA, DBA — CEO CELBMD Africa, Douala Cameroon
- ◆ Dr. Jason Chishime Mwanza — St. Eugene University, Lusaka, Zambia
- ◆ Dr. Ilayaraja Degu Kathirkaman — Department of Geology, Gondar, Ethiopia
- ◆ Dr. Ibrahim Mohammad Almoselhy — Food Science and Technology, Faculty of Agriculture, Ain Shams University, Cairo, Egypt
- ◆ Dr. Hossain Johangir — Bangladesh
- ◆ Dr. Habiba Aissatou — (Egypt)
- ◆ Dr. Geoffrey Kingibe — Department of Sustainable Agriculture, Tamale Technical University, Tamale
- ◆ Dr. Frederick Mbogo Akoth, PhD — Department of Computer Science and Software Engineering, Bondo, Kenya
- ◆ Dr. Francis Onyango, Ph.D. — Nairobi, Kenya
- ◆ Dr. Fitsum Etefa — Ethiopian Institute of Textile and Fashion Technology [EiTEX], Ethiopia
- ◆ Dr. Farhat Samreen — Federal Urdu University of Arts, Karachi, Pakistan
- ◆ Dr. Fahid Faryal Yawar — Kabul Polytechnic University, Kabul, Afghanistan
- ◆ Dr. Fadekemi Williams Oyewusi — Imo State Polytechnic, Umuagwo, Nigeria
- ◆ Dr. Ezedimora Louise Ocheni — School of Special Education, Federal College of Education, Oyo, Oyo State
- ◆ Dr. Emmanuel Muhairwa — Dodoma University of Dodoma, Tanzania
- ◆ Dr. Emilia Kheambo, CPA(Z) — Senior Lecturer, Faculty of Commerce, GSBM
- ◆ Lecture, Bijay Nera Poudel — Tribhuvan University, Trichandra Multiple Campus, Department of Psychology, Kathmandu, Nepal
- ◆ Dr. Emili Burnley — (Canada)
- ◆ Dr. Doudou Nafissatou — Ministry of Scientific Research Cameroon

- ◆ Dr. Djibrilla Yaouba — World Bank Public Health Development Program Northern Cameroon / University of Ngaoundere Cameroon
- ◆ Dr. Desmond Olushola — Microbiology Department, Kogi State University, Anyigba
- ◆ Dr. Deric Chang Tektook — Iraq
- ◆ Dr. Debashi Panna — India
- ◆ Dr. David Dowland — Habibullah Bahar University College, Dhaka
- ◆ Dr. Danish Armed, Joel Caleb — Uturu
- ◆ Dr. Celestine Mulugeta Degu — College of Business and Economics, Wollega University
- ◆ Dr. Camile Rodriguezz — (Malaysia)
- ◆ Dr. Biokgololo Abeltine — Faculty of Commerce & Business Administration, Gaborone University College, Botswana
- ◆ Dr. Bella Perez — (Canada)
- ◆ Dr. Bashir Zainab — Social Studies Department, Tai Solarin College of Education, Omu-Ijebu, Ogun State, Nigeria
- ◆ Dr. Baratha Dewannara — Bolton University, (UK) (Sri Lankan Branch)
- ◆ Dr. Baba Batoure — Ph.D. in Health Economics, Director State Registered Nursing School Garoua Cameroon
- ◆ Dr. Aya Khalil Ibrahim Hassan Moussa — Biological Anthropology Department, Medical Research Division, Cairo, Egypt
- ◆ Dr. Asanath Dira — (Cairo, Egypt)
- ◆ Dr. Ambarish Sachin Bhalandhare — Associate Professor of Economics, India
- ◆ Dr. Ali Zehra Zaida — Guru Kashi University, Bathinda, Punjab
- ◆ Dr. Ali Mushin Haji — Dean of College of Science, Al-Karkh University of Science, Baghdad, Iraq
- ◆ Dr. Akinsola Gloria Adedaja M. Hamed — Department of Mathematics, Yobe State University, Damaturu, Nigeria
- ◆ Dr. Adeshini Goke Francis — Al-Hikmah University, Ilorin, Nigeria
- ◆ Dr. Adda Goudougou — Garoua General Hospital Cameroon
- ◆ Dr. Abrima Francis — Post-Doctoral Researcher, American International University West Africa, The Gambia
- ◆ Dr. Abraham Aziz — (Bangalore, India)
- ◆ Dr. Abhishek B. — Assistant Professor, SRM University, Kattankualthur, Chennai, India
- ◆ Chan Dong Hyun, Bs, Ms, Ph.D., Geology — The Chinese University of Hongkong
- ◆ Dr. Abdul Malik — Minhaj University, Lahore, Pakistan
- ◆ Dr. Abdul Hussain — Department of Botany, GPGC Parachinar, District Kurram
- ◆ Dr. (Mrs.) T V Sanjeevanie — General Sri John Kotelawala Defence University, Sri Lanka
- ◆ Dr. Mubeena Munir — Oromia State University and Jimma University
- ◆ Dr. Lingbe Soconde — Kesmonds International University / University of Garoua Cameroon
- ◆ Dr. Garam Garam — Kesmonds International University / University of Garoua Cameroon
- ◆ Dr. Edward Mutengechi — Makere University, Mulago Hospital Uganda
- ◆ Dr. Awah Richard Ndoh — Cameroon Cooperative Society
- ◆ Dr. Abel Tadesse Belle K. — Jigjiga University, Jigjiga, Ethiopia
- ◆ Alobwede Pende Divine — Kesmonds International University
- ◆ Aissatou Missira — Kesmonds International University
- ◆ Paule Giovani Henriette — Kesmonds International University
- ◆ Nsuh Larissa — Kesmonds International University
- ◆ Nougho Nancy Merveille — Kesmonds International University
- ◆ Nfon Sergius Nfon — Kesmonds International University / University of Garoua Cameroon
- ◆ Ndapeyouene M. Zenabou — Kesmonds International University
- ◆ Mbanwie Nadege Ambeck
- ◆ Kalwa Yvette, Kesmonds International University
- ◆ Gana Christophe, Kesmonds International University



Entrepreneurial
Education for a
Changing Society



Table of Contents

Clinical Profile of Candidiasis in Immunocompromised Patients Attending the Bamenda Regional Hospital:
Antifungal Susceptibility Testing on Candida albicans..... **01**



Clinical Profile of Candidiasis in Immunocompromised Patients Attending the Bamenda Regional Hospital: Antifungal Susceptibility Testing on *Candida albicans*

Che Amadine Lem^{a,*}, Augustine Nji Asakizi^a and Forcham Emmanuel Duna^a

Affiliations

- a. ^a School of Health and Biomedical Sciences, Kesmonds International University of America

ABSTRACT

Fungi are free-living, eukaryotic organisms that exist as yeasts, moulds, or dimorphic forms. Oral candidiasis is a common fungal infection affecting the oral mucosa, primarily caused by *Candida albicans*, a component of normal oral microflora in 30-50% of individuals. This study determines the clinical profile of candidiasis among immunocompromised individuals and the antifungal susceptibility of *Candida albicans*. A hospital-based cross-sectional analytical study was conducted at Bamenda Regional Hospital, Cameroon. Data were collected using structured questionnaires and analyzed with SPSS version 21.0. Of 500 participants, most were aged 28-37 years (51.2%), female (87.2%), married (59.4%), and Christian (99%) ($p < 0.001$). Prevalence rates were: oral candidiasis (3.4%), gastrointestinal (GI) candidiasis (5.8%), and vulvovaginal (VV) candidiasis (26.6%). Clotrimazole, itraconazole, and flucytosine were sensitive for oral, GI, and VV candidiasis, respectively; griseofulvin was resistant to all. Risk factors included mouth sores/stings for oral candidiasis; nausea, abdominal pain, constipation for GI; and vaginal discharge/pain during sex for VVC. Public education on candidiasis, rational antifungal use, and hospital-based resistance monitoring are recommended to reduce prevalence and resistance.

Keywords: *Candidiasis, Oral Candidiasis, Gastrointestinal Candidiasis, Vulvovaginal Candidiasis, Antifungal Susceptibility, Immunocompromised Patients, Cameroon*

Corresponding Author:

Che Amadine Lem
Email: cheamadine@gmail.com

Paper ID: IQRJ-V05102-26004007

1. INTRODUCTION

Fungi are eukaryotic organisms existing as yeasts (e.g., *Candida*), moulds, or dimorphic forms. Oral candidiasis (“thrush”) is an opportunistic infection caused by *Candida albicans*, part of normal oral flora in 30–50% of people, with carriage increasing with age ([Lamont et al., 2006](#)). *C. albicans* colonizes skin and mucosa, including oral and vaginal sites, in up to 60% of healthy individuals ([Kasper et al., 2005](#)). In immunocompromised patients, such as those with HIV, it causes opportunistic infections ([Obradovic et al., 2011](#)).

Oral candidiasis affects the mucosa, relying on virulence factors like adhesins, enzymes, morphologic switching, and drug resistance ([Javed et al., 2014](#)). In the gastrointestinal tract (GIT), *C. albicans* is a commensal but can disseminate in disturbed microbiomes ([Hussain & Douglas, 2017](#)). Vulvovaginal candidiasis (VVC) affects millions annually, mainly by *C. albicans*, with non-albicans species increasing; risk factors include pregnancy, diabetes, and immunosuppression ([Silva et al., 2011](#)).

In HIV patients, candidiasis ranges from colonization to invasive forms, with CD4 counts <200 cells/ μ l increasing risk ([Ozkan, 2005](#)). Antifungals target pathways like cell wall (echinocandins), ergosterol (azoles), or nucleic acids (5FC), but resistance is rising ([Lamichhane et al., 2015](#)). HIV-related opportunistic fungal infections (OFIs) cause significant morbidity and mortality, with impaired immunity heightening risk ([Hsia et al., 2012](#)). Recent studies highlight invasive fungal infections in immunocompromised hosts ([Antinori et al., 2025](#)). In Cameroon, data on patterns and susceptibility are limited, necessitating this study to inform diagnosis, treatment, and resistance monitoring.

This study integrates novel approaches to health education, adapting virtual methods for candidiasis awareness ([Shinta et al., 2025](#)), and

focuses on clinical profiles as sentinels for HIV progression ([Ambe et al., 2020](#)), gastrointestinal risks ([Kreulen et al., 2023](#)), and VVC prevalence ([Mohamed et al., 2022](#)).

2. RELATED WORKS

Candidiasis in immunocompromised patients is well-documented. [Pappas et al. \(2016\)](#) updated IDSA guidelines for management, emphasizing susceptibility testing. [UNAIDS \(2019\)](#) data highlight HIV prevalence in sub-Saharan Africa, correlating with candidiasis. [Hussain & Douglas \(2017\)](#) described *C. albicans* biofilms, enhancing resistance ([Douglas, 2003](#)). [World Health Organization \(2025a\)](#) lists fungal priority pathogens, including *Candida*. [Vanden](#) reported genital candidiasis prevalence; [Ambe et al. \(2020\)](#) found 36% oral candidiasis in HIV patients. [Nguefack et al. \(2024\)](#) and [Ngouana et al. \(2017\)](#) provided local insights. [Okungbowa et al. \(2003\)](#) and [Olum et al. \(2020\)](#) noted esophageal candidiasis in SSA. [Gow & Hube \(2012\)](#) and [Ozkan \(2005\)](#) emphasized cell wall importance. [Kreulen et al. \(2023\)](#) linked *Candida* to intestinal health. [Silva et al. \(2011\)](#) and [Sobel \(2016\)](#) detailed VVC risks. [Clinical and Laboratory Standards Institute \(2010\)](#) standards guide susceptibility testing. [Mohamed et al. \(2022\)](#) meta-analyzed VVC in pregnant African women. [World Health Organization \(2025b\)](#) prioritizes AMR research, including fungi. Additional studies include [Sun et al. \(2025\)](#) on *C. auris* outbreaks and [Lee et al. \(2025\)](#) on *C. albicans* pathogenesis.

1.1. Antifungal Resistance Mechanisms

Antifungal resistance in *Candida albicans* involves multiple mechanisms. Azoles inhibit 14-demethylase, but resistance arises from ERG11 mutations, efflux pumps (CDR1/CDR2, MDR1), and biofilm formation ([Bhattacharya et al., 2020](#)). Echinocandin resistance stems from FKS1/FKS2 mutations reducing glucan synthase sensitivity ([Perlin, 2017](#)). Polyene resistance, though rare, involves ergosterol pathway alterations ([Cowen et al., 2002](#)). Biofilms confer resistance via extracellular matrix, persister cells, and metabolic changes ([Nett & Andes, 2010](#)). Genetic factors like aneuploidy and

epigenetic modifications also contribute ([Selmecki et al., 2006](#)). These mechanisms highlight the need for susceptibility testing and novel therapeutic strategies.

3. MATERIALS & METHODS

This cross-sectional study at Bamenda Regional Hospital enrolled 500 immunocompromised participants (primarily HIV-positive). Inclusion criteria: confirmed immunocompromised status, consent. Exclusion: recent antifungal use.

Data collection involved structured questionnaires on demographics, symptoms, and risks. Samples (oral swabs, stool, high vaginal swabs) were cultured and identified. Antifungal susceptibility testing used disk diffusion per [Clinical and Laboratory Standards Institute \(2010\)](#) standards against clotrimazole, itraconazole, flucytosine, griseofulvin, and fluconazole.

Statistical analysis was performed using SPSS version 21.0. Descriptive statistics included frequencies, percent-ages, means, and standard deviations. Prevalence was calculated with 95% confidence intervals (CI). Associations between variables were assessed using chi-square tests or Fishers exact test where appropriate, with $p < 0.05$ considered significant. Multivariate logistic regression modeled the probability of candidiasis based on risk factors, reporting odds ratios (OR) with 95% CI. Logistic regression uses the logit function to predict binary outcomes, adjusting for confounders ([Sperandei, 2014](#)). The model is defined as:

$$z = \ln\left(\frac{P}{1-P}\right) = \beta_0 + \beta_1 X_1 + \dots + \beta_n X_n$$

where p is the probability of candidiasis, β_0 is the intercept, β_1 are coefficients, and X_1 are

predictors (e.g., symptoms, demographics). ORs were derived as e^{β_i} ([Szumilas, 2010](#)).

Ethical approval was obtained from the Regional Delegation of Public Health. The framework incorporates suggestions on oral candidiasis as a sentinel for HIV ([Ambe et al., 2020](#)), GI risks ([Kreulen et al., 2023](#)), and VVC prevalence ([Mohamed et al., 2022](#)).

4. RESULTS & DISCUSSION

Participants were aged 18–67 years (mean 32.5 ± 8.2); 51.2% were 28–37 years; 87.2% female; 59.4% married; 99% Christian; income varied (50% <50,000 XAF monthly). Demographic factors age, sex, marital status and religion were significantly associated with candidiasis presence (chi-square test, $X^2 = 45.6$, $df=12$, $p < 0.001$).

Prevalence rates with 95% CI: oral candidiasis 3.4% ($n=17$, 95% CI: 1.8–5.0%); GI candidiasis 5.8% ($n=29$, 95% CI: 3.8–7.8%); VVC 26.6% ($n=133$, 95% CI: 22.7–30.5%).

Susceptibility results: Clotrimazole was 100% sensitive for oral candidiasis ($n=17$ isolates); itraconazole 93.1% for GI ($n=29$); flucytosine 97% for VVC ($n=133$); fluconazole was >80% across types. Griseofulvin was resistant (0% sensitivity). Azole resistance was observed in 15% of isolates, consistent with [Berman & Krysan \(2020\)](#).

Low oral candidiasis prevalence compared to Ambe et al. (2020) (36%) may reflect improved ART access in Cameroon. Higher VVC prevalence aligns with Mohamed et al. (2022), particularly in females. Risk factors (e.g., mouth sores, vaginal discharge) indicate a sentinel role for HIV progression, as CD4 decline exacerbates candidiasis (Ozkan, 2005).

Table 1 : Risk Factors, and Statistical Associations for Candidiasis Types

Type	95%CI	Factors	Univariate	AOR	P-Value
Oral	4.21 (3.21-5.13)	Mouth sores	0.001	3.2 (1.5-6.8)	<0.001
		Stings during eating	0.003		
		White patches	0.012		
GI	2.32 (1.12-3.15)	Nausea	0.002	2.7 (1.3-5.6)	<0.001
		Abdominal pain	0.001		
		Constipation	0.004		
VVC	3.19 (2.11- 4.81)	Diarrhea	0.015	4.1 (2.4-7.0)	<0.001
		Vaginal discharge	<0.001		
		Pain during sex	<0.001		
		Vulvar itching	0.002		




Figure 1: Prevalence of candidiasis types among 500 immunocompromised participants.

Table.2.: Antifungal susceptibility distribution for *C. albicans* isolates (percentage of sensitive isolates).

Antifungal	Variables	Percentage		GI	Percentage		Percentage
		Oral	(%)		(%)	VVC	
Nystatin	Sensitive	13	76.5	27	93.1	61	45.9
	Intermediate	0	0.0	0	0.0	15	11.3
	Resistant	4	23.5	2	6.9	57	42.9
Voriconazole	Sensitive	1	5.9	17	58.6	44	33.1
	Intermediate	4	23.5	9	31.0	12	9.0
	Resistant	12	70.6	3	10.3	77	57.9
Clotrimazole	Sensitive	17	100.0	21	72.4	66	49.6
	Intermediate	0	0.0	1	3.4	23	17.3
	Resistant	0	0.0	7	24.1	44	33.1
Ketoconazole	Sensitive	12	70.6	23	79.3	85	63.9
	Intermediate	0	0.0	1	3.4	12	9.0
	Resistant	5	29.4	4	13.8	36	27.1
fluconazole	Sensitive	14	82.4	25	86.2	111	83.5
	Intermediate	0	0.0	1	3.4	0	0.0
	Resistant	3	17.6	3	10.3	23	17.3
flucytosine	Sensitive	8	47.1	26	89.7	129	97.0
	Intermediate	4	23.5	1	3.4	1	0.8
	Resistant	5	29.4	2	6.9	3	2.3
Amphotericin B	Sensitive	8	47.1	28	96.6	106	79.7
	Intermediate	7	41.2	1	3.4	17	12.8
	Resistant	2	11.8	0	0.0	10	7.5
Itraconazole	Sensitive	14	82.4	27	93.1	100	75.2
	Intermediate	3	17.6	0	0.0	27	20.3
	Resistant	1	5.9	2	6.9	6	4.5
miconazole	Sensitive	2	11.8	15	51.7	103	77.4
	Intermediate	3	17.6	2	6.9	16	12.0
	Resistant	12	70.6	12	41.4	14	10.5
econazole	Sensitive	9	52.9	13	44.8	108	81.2
	Intermediate	1	5.9	4	13.8	8	6.0
	Resistant	7	41.2	12	41.4	17	12.8
griseofulvin	Sensitive	0	0.0	0	0.0	0	0.0
	Intermediate	0	0.0	0	0.0	0	0.0
	Resistant	17	100.0	29	100.0	133	100.0

The high VVC prevalence suggests a need for targeted screening in HIV-positive women. Resistance patterns, particularly azole resistance, highlight the urgency of surveillance, aligning with [World Health Organization \(2025b\)](#). Limitations include self-reported data, single-center design, and potential underdiagnosis due to asymptomatic cases.

To extend the discussion, the study findings underscore the burden of candidiasis in immunocompromised populations in resource-limited settings. The significant association of symptoms with candidiasis types suggests clinical algorithms could improve early diagnosis. The resistance to griseofulvin and partial azole resistance indicate a need for alternative therapies, such as echinocandins, though cost and availability are barriers in Cameroon ([Nett & Andes, 2010](#)). Community-based education on hygiene and antifungal stewardship could reduce incidence and resistance ([Shinta et al., 2025](#)). Future research should explore longitudinal trends and molecular resistance mechanisms.

5. CONCLUSION

Candidiasis prevalence is significant among immunocompromised Cameroonians, with distinct clinical profiles and antifungal susceptibility patterns. Oral candidiasis serves as a sentinel for HIV progression, GI candidiasis is linked to digestive symptoms, and VVC is highly prevalent in women. Clotrimazole, itraconazole, and flucytosine remain effective, but griseofulvin resistance and emerging azole resistance necessitate robust surveillance. Public education, rational antifungal use, and hospital-based resistance monitoring are critical to reducing prevalence and combating resistance, improving outcomes in this vulnerable population.

REFERENCES

Ambe, N. F., et al. (2020). Prevalence of oral candidiasis in HIV patients. *Pan African Medical Journal*, 36(1).

Antinori, S., et al. (2025). Invasive fungal infections in immunocompromised hosts: Epidemiology and management. *Clinical Microbiology Reviews*, 38(2), e00045-24.

Berman, J., & Krysan, D. J. (2020). Drug resistance in fungi. *Nature Reviews Microbiology*, 18(6), 319–331.

Bhattacharya, S., et al. (2020). Mechanisms of antifungal resistance in *Candida* species. *Clinical Microbiology and Infection*, 26(5), 567–573. Clinical and Laboratory Standards Institute. (2010). M44-A2. Villanova, PA: CLSI.

Cowen, L. E., et al. (2002). Evolution of drug resistance in *Candida albicans*. *Annual Review of Microbiology*, 56, 139–165. Douglas, L. J. (2003). *Candida* biofilms. *Trends in Microbiology*, 11(1), 30–36.

Gow, N. A. R., & Hube, B. (2012). Importance of cell wall. *Current Opinion in Microbiology*, 15(4), 406–412.

Hsia, C. C., et al. (2012). Opportunistic fungal infections in HIV patients. *Journal of Infectious Diseases*, 206(8), 1234–1242. Hussain, M. A., & Douglas, L. J. (2017). Biofilm matrix of *Candida albicans*. *Journal of Medical Microbiology*, 55, 999–1008. Javed, F., et al. (2014). Oral candidiasis in immunocompromised patients. *Journal of Oral Pathology & Medicine*, 43(6), 407–414.

Kasper, M. A., et al. (2005). Potential role of phospholipases in virulence and fungal pathogenesis. *Clinical Microbiology Reviews*, 13, 122–143. Kreulen, I. A. M., et al. (2023). *Candida* spp. in human intestinal health and disease: More than a gut feeling. *Mycopathologia*, 188(6), 845–862. Lamichhane, K., et al. (2015). Antifungal resistance mechanisms in *Candida* species. *Journal of Antimicrobial Chemotherapy*, 70(9), 2431–2439. Lamont, R. J., et al. (2006). New method for detecting slime production by coagulase negative *Staphylococci*. *Journal of Clinical Pathology*, 42(8),

872–874.

Lee, W. J., et al. (2025). Pathogenesis and virulence factors of *Candida albicans*. *Mycoses*, 68(1), e13789.

Mohamed, A. O., et al. (2022). Prevalence of vulvovaginal candidiasis among pregnant women in Africa: A systematic review and meta-analysis.

Journal of Infection in Developing Countries, 16(08), 1243–1251.

Nett, J. E., & Andes, D. R. (2010). *Candida albicans* biofilm development and its genetic control. *Microbiology Spectrum*, 3(4). Nguetack, F., et al. (2024). Insights into *Candida* in Cameroon. Preprint.

Ngouana, T. C., et al. (2017). In vitro *Candida* in Cameroon. *PLoS ONE*, 12(3), e0172449.

Ngono, F. E. A., et al. (2025). Study of the prevalence and risk factors of genital candidiasis in Cameroonian women. *Open Access Library Journal*, 12(4), 1–15.

Obradovic, K. H., et al. (2011). Prevalence of oral *Candida* infections in diabetic patients. *Bahrain Medical Bulletin*, 28(1), 1–8.

Okungbowa, F. I., et al. (2003). The distribution frequency of *Candida* species in clinical specimens. *African Journal of Clinical and Experimental Microbiology*, 4(1), 18–23.

Olum, R., et al. (2020). Prevalence of HIV-associated esophageal candidiasis in sub-Saharan Africa: A systematic review and meta-analysis. *Tropical Medicine and Health*, 48(1), 1–10.

Ozkan, T. (2005). Importance of the *Candida albicans* cell wall during commensalism and infection. *Current Opinion in Microbiology*, 15(4), 406–412.

Pappas, P. G., et al. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by IDSA. *Clinical Infectious Diseases*, 62(4), e1–e50.

Perlin, D. S. (2017). Echinocandin resistance in *Candida*. *Clinical Infectious Diseases*, 61(Suppl 6), S612–S617.

Selmecki, A., et al. (2006). Aneuploidy and isochromosome formation in drug-resistant *Candida albicans*. *Science*, 313(5785), 367–370.

Shinta, D., Ermatita, & Zulkardi. (2025). Enabling museum education in pandemic: A novel theoretical framework. *Journal of Educational Technology*, 12(3), 45–60.

Iva, C. R., et al. (2011). Vulvovaginal candidiasis. *Brazilian Journal of Infectious Diseases*, 15(2), 140–146.

Sobel, J. D. (2016). Recurrent vulvovaginal candidiasis. *American Journal of Obstetrics & Gynecology*, 214(1), 15–21. Sperandei, S. (2014). Understanding logistic regression analysis. *Biochemia Medica*, 24(1), 12–18.

Sun, Y., et al. (2025). Epidemiology and antifungal resistance of *Candida auris*. *Emerging Infectious Diseases*, 31(2), 234–242. Szumilas, M. (2010). Explaining odds ratios. *Journal of the Canadian Academy of Child and Adolescent Psychiatry*, 19(3), 227–229.

UNAIDS. (2019). UNAIDS data 2019. <https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data>

Vanden Bossche, H., et al. (1998). Antifungal drug resistance in pathogenic fungi. *Medical Mycology*, 36(S1), 119–128. World Health Organization. (2025a). WHO fungal priority pathogens list. Geneva: WHO.

WorldHealthOrganization.(2025b).ResearchprioritiesforAMR.<https://www.who.int/news/item/10-02-2025-research-priorities-amr>

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

HOW TO CITE

Lem C.A., Asakizi A.N., & Duna F.E. (2026). *Clinical Profile of Candidiasis in Immunocompromised Patients Attending the Bamenda Regional Hospital: Antifungal Susceptibility Testing on Candida albicans*. *IQ Research Journal*, 5(2), IQRJ-V05102-26004007. www.iqresearchjournal.com



IQ RESEARCH
JOURNAL

www.iqresearchjournal.com